Doribax
(Doripenem)ApprovedSmall molecule
ShionogiDoripenem is an antibiotic used to treat serious bacterial infections, including those in the abdomen, urinary tract, and bloodstream. It works by killing bacteria that cause infections.[2] Doribax is currently approved and in use across 13 indications[4].[1]
Doribax is one of 265 small molecule programs targeting Bacterial Disease. It is currently in Approved.
13
Indications
23
Total Trials
0
Active Trials
264
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Primaxin
PfizerPreclinical
Jakafi
IncytePreclinical
Neutrexin
WWest Japan Thoracic Oncology Group
Preclinical
Primsol
CConrado Roberto Hoffmann Filho
Preclinical
Retrovir
BBp Consulting, Inc
Preclinical
Pepcid
KKenvue Brands
Preclinical
Aciphex
Akero TherapeuticsPreclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Urinary Tract Infection6 trials
Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
Completed·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210990·403 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210990·403 enrolledShow 3 more trials
Complicated Intra-abdominal Infections3 trials
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00229060·483 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00229060·483 enrolledDoripenem in the Treatment of Complicated Intra-Abdominal Infections
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210938·478 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00210938·478 enrolledVentilator-Associated Pneumonia3 trials
Pneumonia3 trials
Doripenem in the Treatment of Hospital-Acquired Pneumonia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00211003·240 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00211003·240 enrolledA Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00515034·146 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00515034·146 enrolled7 more indications
Prospective1 trial
Bacterial Pneumonia1 trial
Single Dose1 trial
Adult Subject1 trial
Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects
Completed·—·Phase 1·NCT00925392·40 enrolled
Critically Ill1 trial
Pediatric Patients1 trial
Unspecified1 trial
Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients
Completed·—·Phase 4·NCT01401010·12 enrolled
Regulatory
FDA Approval Timeline[5]
Oct 5, 2010
DORIBAX
NDA NDA022106
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Doribax drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Doripenem. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]